How many insider trades does FilingIQ track for IGC?

FilingIQ tracks 303 Form 4 insider transactions for IGC (IGC Pharma, Inc.), covering filings from May 13, 2015 onwards. 3 of those are dated within the last 90 days.

Are IGC insiders net buyers or net sellers?

Across the full Form 4 history for IGC, 1 transactions (0%) were open-market purchases and 37 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IGC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is IGC in?

IGC Pharma, Inc. (IGC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.07M.

IGC insider trading

NYSE American Healthcare

IGC Pharma, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

303

Last 90 days

Buys / sells

0% / 12%

Market cap

$26.07M

About IGC Pharma, Inc.

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Company website: igcpharma.com

IGC insider activity at a glance

FilingIQ tracks 303 insider transactions for IGC in filings since May 13, 2015. The most recent transaction is dated Sep 25, 2026.

Across the full history, 1 open-market purchases and 37 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IGC insider trades is 58.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IGC trades on FilingIQ Raw filings on SEC EDGAR

Latest IGC Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for IGC?: FilingIQ tracks 303 Form 4 insider transactions for IGC (IGC Pharma, Inc.), covering filings from May 13, 2015 onwards. 3 of those are dated within the last 90 days.
Are IGC insiders net buyers or net sellers?: Across the full Form 4 history for IGC, 1 transactions (0%) were open-market purchases and 37 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IGC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is IGC in?: IGC Pharma, Inc. (IGC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.07M.

Methodology & sources

Every IGC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.